The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature - PubMed (original) (raw)
The addition of AG-013736 to fractionated radiation improves tumor response without functionally normalizing the tumor vasculature
Bruce M Fenton et al. Cancer Res. 2007.
Abstract
Although antiangiogenic strategies have proven highly promising in preclinical studies and some recent clinical trials, generally only combinations with cytotoxic therapies have shown clinical effectiveness. An ongoing question has been whether conventional therapies are enhanced or compromised by antiangiogenic agents. The present studies were designed to determine the pathophysiologic consequences of both single and combined treatments using fractionated radiotherapy plus AG-013736, a receptor tyrosine kinase inhibitor that preferentially inhibits vascular endothelial growth factor receptors. DU145 human prostate xenograft tumors were treated with (a) vehicle alone, (b) AG-013736, (c) 5x2 Gy/wk radiotherapy fractions, or (d) the combination. Automated image processing of immunohistochemical images was used to determine total and perfused blood vessel spacing, overall hypoxia, pericyte/collagen coverage, proliferation, and apoptosis. Combination therapy produced an increased tumor response compared with either monotherapy alone. Vascular density progressively declined in concert with slightly increased alpha-smooth muscle actin-positive pericyte coverage and increased overall tumor hypoxia (compared with controls). Although functional vessel endothelial apoptosis was selectively increased, reductions in total and perfused vessels were generally proportionate, suggesting that functional vasculature was not specifically targeted by combination therapy. These results argue against either an AG-013736- or a combination treatment-induced functional normalization of the tumor vasculature. Vascular ablation was mirrored by the increased appearance of dissociated pericytes and empty type IV collagen sleeves. Despite the progressive decrease in tumor oxygenation over 3 weeks of treatment, combination therapy remained effective and tumor progression was minimal.
Similar articles
- Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.
Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE. Timke C, et al. Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893. Clin Cancer Res. 2008. PMID: 18381963 - Pathophysiological effects of vascular endothelial growth factor receptor-2-blocking antibody plus fractionated radiotherapy on murine mammary tumors.
Fenton BM, Paoni SF, Ding I. Fenton BM, et al. Cancer Res. 2004 Aug 15;64(16):5712-9. doi: 10.1158/0008-5472.CAN-04-0434. Cancer Res. 2004. PMID: 15313911 - Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O'Connor P, Shalinsky DR, Bender SL. Hu-Lowe DD, et al. Clin Cancer Res. 2008 Nov 15;14(22):7272-83. doi: 10.1158/1078-0432.CCR-08-0652. Clin Cancer Res. 2008. PMID: 19010843 - Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction.
Wachsberger P, Burd R, Dicker AP. Wachsberger P, et al. Clin Cancer Res. 2003 Jun;9(6):1957-71. Clin Cancer Res. 2003. PMID: 12796357 Review. - Current development status of small-molecule vascular disrupting agents.
Chaplin DJ, Horsman MR, Siemann DW. Chaplin DJ, et al. Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Curr Opin Investig Drugs. 2006. PMID: 16784022 Review.
Cited by
- Approved Small-Molecule ATP-Competitive Kinases Drugs Containing Indole/Azaindole/Oxindole Scaffolds: R&D and Binding Patterns Profiling.
Zhang H, He F, Gao G, Lu S, Wei Q, Hu H, Wu Z, Fang M, Wang X. Zhang H, et al. Molecules. 2023 Jan 17;28(3):943. doi: 10.3390/molecules28030943. Molecules. 2023. PMID: 36770611 Free PMC article. Review. - Early effects of low dose bevacizumab treatment assessed by magnetic resonance imaging.
Gaustad JV, Simonsen TG, Smistad R, Wegner CS, Andersen LM, Rofstad EK. Gaustad JV, et al. BMC Cancer. 2015 Nov 14;15:900. doi: 10.1186/s12885-015-1918-1. BMC Cancer. 2015. PMID: 26573613 Free PMC article. - CT spectral imaging for monitoring the therapeutic efficacy of VEGF receptor kinase inhibitor AG-013736 in rabbit VX2 liver tumours.
Lv P, Liu J, Yan X, Chai Y, Chen Y, Gao J, Pan Y, Li S, Guo H, Zhou Y. Lv P, et al. Eur Radiol. 2017 Mar;27(3):918-926. doi: 10.1007/s00330-016-4458-4. Epub 2016 Jun 10. Eur Radiol. 2017. PMID: 27287476 - Properdistatin inhibits angiogenesis and improves vascular function in human melanoma xenografts with low thrombospondin-1 expression.
Gaustad JV, Simonsen TG, Andersen LM, Rofstad EK. Gaustad JV, et al. Oncotarget. 2016 Nov 22;7(47):76806-76815. doi: 10.18632/oncotarget.12695. Oncotarget. 2016. PMID: 27756886 Free PMC article. - Irinotecan synergistically enhances the antiproliferative and proapoptotic effects of axitinib in vitro and improves its anticancer activity in vivo.
Canu B, Fioravanti A, Orlandi P, Di Desidero T, Alì G, Fontanini G, Di Paolo A, Del Tacca M, Danesi R, Bocci G. Canu B, et al. Neoplasia. 2011 Mar;13(3):217-29. doi: 10.1593/neo.101334. Neoplasia. 2011. PMID: 21390185 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical